共 26 条
- [1] Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116).[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Rosen, EzraSilverman, Ian M.Fontana, ElisaLee, Elizabeth KatherineSpigel, David R.Hojgaard, MartinLheureux, StephanieMettu, Niharika B.Carneiro, Benedito A.Carter, LouisePlummer, Elizabeth RuthSchonhoft, Joseph D.Ulanet, DanielleManley, PeterReis-Filho, Jorge S.Xu, YiRimkunas, VictoriaKoehler, MariaYap, Timothy A.
- [2] First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)De Bono, Johann S.Tan, David Shao PengCaldwell, ReeceTerbuch, AngelikaGoh, Boon C.Heong, ValerieHaris, Noor MdBashir, SairaHong, David S.Meric-Bernstam, FundaBordia, SonalLiu, LiWilkinson, GaryHreiki, JosephWengner, AntjeFischer, KerstinBoix, OliverLagkadinou, EleniPlummer, ElizabethYap, Timothy A.
- [3] First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors[J]. CANCER DISCOVERY, 2021, 11 (01) : 80 - 91Yap, Timothy A.Tan, David S. P.Terbuch, AngelikaCaldwell, ReeceGuo, ChristinaGoh, Boon CherHeong, ValerieHaris, Noor R. MdBashir, SairaDrew, YvetteHong, David S.Meric-Bernstam, FundaWilkinson, GaryHreiki, JosephWengner, Antje M.Bladt, FriedhelmSchlicker, AndreasLudwig, MatthiasZhou, YinghuiLiu, LiBordia, SonalPlummer, RuthLagkadinou, Elenide Bono, Johann S.
- [4] Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (09):Fontana, ElisaRosen, EzraLee, Elizabeth K.Hojgaard, MartinMettu, Niharika B.Lheureux, StephanieCarneiro, Benedito A.Cote, Gregory M.Carter, LouisePlummer, RuthMahalingam, DevalingamFretland, Adrian J.Schonhoft, Joseph D.Silverman, Ian M.Wainszelbaum, MarisaXu, YiUlanet, DanielleKoehler, MariaYap, Timothy A.
- [5] Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations[J]. CANCER RESEARCH, 2023, 83 (08)Yap, Timothy A.Yadav, SiddharthaHerzberg, BenjaminCarneiro, Benedito A.Fontana, ElisaHojgaard, MartinPishvaian, Michael J.Plummer, RuthWerner, Theresa L.Sahai, VaibhavLheureux, StephanieLee, Elizabeth K.Mettu, Niharika B.Cote, Gregory M.Schonhoft, Joseph D.Rimkunas, VictoriaSilverman, Ian M.Wainszelbaum, MarisaPeltz, GersonFretland, Adrian J.Fei, KezhenUlanet, DanielleKim, InsilKoehler, MariaRosen, EzraCecchini, Michael
- [6] First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors[J]. CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2057 - 2067Yap, Timothy A.Tolcher, Anthony W.Plummer, RuthMukker, Jatinder KaurEnderlin, MartaHicking, ChristineGrombacher, ThomasLocatelli, GiuseppeSzucs, ZoltanGounaris, Ioannisde Bono, Johann S.
- [7] First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Yap, Timothy A.Dumbrava, Ecaterina ElenaAhnert, Jordi RodonHong, David S.Pant, ShubhamKarp, Daniel D.Piha-Paul, Sarina Anne AnneSubbiah, VivekTsimberidou, Apostolia MariaFu, SiqingJanku, FilipMontez, SandraAhmad-Taha, Majd T.Guerrero, DarleneNazarenko, Natalya N.Moore, YanSoth, MichaelKovacs, JeffHeffernan, Timothy P.Jones, Philip
- [8] Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers[J]. CANCER RESEARCH, 2018, 78 (13)Krebs, Matthew G.Lopez, JuanitaEl-Khoueiry, AnthonyBang, Yung-JuePostel-Vinay, SophieAbida, WassimCarter, LouiseXu, WenIm, Seock-AhPierce, AndrewFrewer, PaulBerges, AlienorCheung, S. Y. AmyStephens, ChristineFelicetti, BrunellaDean, EmmaHollingsworth, Simon J.
- [9] Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Moore, Kathleen N.Jones, Suzanne FieldsKurkjian, CarlaArkenau, Hendrik-TobiasInfante, Jeffrey R.Pant, ShubhamBurris, Howard A.McMeekin, D. ScottGibbons, JayHarrow, KimberlyLiang, ChrisRamsey, SaraBendell, Johanna C.
- [10] First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Burris, H.Rodon, J.Sharma, S.Herbst, R. S.Tabernero, J.Infante, J. R.Silva, A.Demanse, D.Hackl, W.Baselga, J.